11 completed, 6 active not recruiting, 2 recruiting, 2 terminated. 8 Phase 2, 6 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Active not recruiting 2, Completed 2, Terminated 2, Recruiting 1, Withdrawn 1 |
| Phase 1 | 6 | Completed 6 |
| Phase 3 | 3 | Active not recruiting 2, Completed 1 |
Follow ritlecitinib: new trials by email Literature Review of ritlecitinib trials Research Report on ritlecitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data ritlecitinib - Alopecia Areata | Active not recruiting | Pfizer | 1 | 2026-08-17 | 2026-10-16 | |
| Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria Ritlecitinib - Chronic Spontaneous Urticaria, CSU | Phase 2 | Withdrawn | Ahuva D Cices | 2025-12-31 | 2025-12-09 | |
| Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US Ritlecitinib - Alopecia Areata | Completed | Pfizer | 300 | 2025-12-22 | 2026-08-10 | |
| A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. Ritlecitinib, Placebo - Hidradenitis Suppurativa | Phase 2 | Active not recruiting | Pfizer | 128 | 2025-11-13 | 2026-10-20 |
| A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings Ritlecitinib - Severe Alopecia Areata | Completed | Pfizer | 123 | 2025-02-03 | 2026-06-10 | |
| Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy Ritlecitinib - Keloid | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 30 | 2024-08-13 | 2026-09-01 |
| Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib Ritlecitinib - Alopecia Areata | Active not recruiting | Pfizer | 450 | 2024-08-07 | 2026-10-06 | |
| Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study Tofacitinib, Baricitinib, Ruxolitinib - Alopecia Areata, Janus Kinase Inhibitors | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 150 | 2024-07-29 | 2024-08-27 | |
| A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food Ritlecitinib - Healthy Volunteers | Phase 1 | Completed | Pfizer | 12 | 2024-05-03 | 2024-08-28 |
| A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults Ritlecitinib - Healthy Volunteers | Phase 1 | Completed | Pfizer | 12 | 2024-02-01 | 2025-04-10 |
| A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo Ritlecitinib, Ritlecitinib 100 mg, Placebo - Vitiligo | Phase 3 | Active not recruiting | Pfizer | 394 | 2024-01-19 | 2026-09-28 |
| A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 Ritlecitinib, Placebo - Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo | Phase 3 | Active not recruiting | Pfizer | 1571 | 2023-11-08 | 2026-10-23 |
| Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo - Diabetes Mellitus, Type 1 | Phase 2 | Active not recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 78 | 2023-10-19 | 2026-09-02 |
| Ritlecitinib in CTCL Ritlecitinib - CTCL, Mycosis Fungoides | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 7 | 2023-05-17 | 2025-07-18 |
| A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants Ritlecitinib - Healthy Volunteers, Adult | Phase 1 | Completed | Pfizer | 12 | 2023-05-09 | 2024-10-16 |
| Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission Ritlecitinib, Placebo, Gluten - Celiac Disease | Phase 2 | Completed | Massachusetts General Hospital | 62 | 2023-03-01 | 2026-10-30 |
| Ritlecitinib for Cicatricial Alopecia PF-06651600 - Cicatricial Alopecia | Phase 2 | Completed | Emma Guttman | 50 | 2022-12-15 | 2026-07-15 |
| A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo Ritlecitinib, Placebo - Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo | Phase 3 | Completed | Pfizer | 607 | 2022-12-01 | 2026-02-27 |
| Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide Ritlecitinib, Tolbutamide - Healthy Volunteers | Phase 1 | Completed | Pfizer | 12 | 2021-11-02 | 2023-10-06 |
| A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults ritlecitinib - Healthy Participants | Phase 1 | Completed | Pfizer | 12 | 2021-09-10 | 2023-08-21 |
Showing 20 of 23. Sign in to see all of them.
Alopecia Areata (7) · Alopecia (3) · Alopecia universalis (2) · Celiac Disease (1) · Chronic Urticaria (1) · Diabetes Mellitus, Type 1 (1) · Hidradenitis Suppurativa (1) · Keloid (1) · Lichen Planus (1) · Mycosis Fungoides (1) · Sezary Syndrome (1) · Vitiligo (1)
Pfizer (16) · Icahn School of Medicine at Mount Sinai (2) · Ahuva D Cices (1) · Emma Guttman (1) · Massachusetts General Hospital (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
United States (19) · Canada (6) · Australia (5) · China (5) · Poland (5) · Germany (4) · Japan (4) · Spain (4) · United Kingdom (4) · Belgium (3) · Bulgaria (3) · Italy (3) · Mexico (3) · Turkey (Türkiye) (3) · South Korea (2)
Ahuva Cices, MD (1) · Emma Guttman, MD, PhD (1) · Emma Guttman-Yassky, MD, PhD (1) · Maureen Leonard, MD (1) · Patrick Brunner, MD (1) · Xianjie Wu, Ph.D (1)
PMID 42171987, PMID 38263353, PMID 38267790, PMID 41917311, PMID 42481842
2023 (2), 2025 (1)